Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02693652
Other study ID # CVI-HBV-002-CT1301
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date October 28, 2014
Est. completion date August 22, 2017

Study information

Verified date November 2023
Source CHA Vaccine Institute Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A single center, open labeled phase I/IIa study to evaluate safety, tolerability and efficacy of a therapeutic hepatitis B vaccine in oral antiviral drug-treated chronic hepatitis B virus carriers


Description:

- Objectives: To explore the appropriate dose of a therapeutic hepatitis B vaccine through the evaluation of safety, tolerability, and efficacy - Subjects: Chronic hepatitis B carrier with normal ALT range - Study hypothesis: The immune tolerance break and strong immune responses in the chronic hepatitis B carrier could be achieved with therapeutic hepatitis B vaccine containing novel adjuvant


Recruitment information / eligibility

Status Completed
Enrollment 53
Est. completion date August 22, 2017
Est. primary completion date August 22, 2017
Accepts healthy volunteers No
Gender All
Age group 19 Years to 60 Years
Eligibility Inclusion Criteria: 1. Adult between 19 to 60 years of age 2. Chronic hepatitis B carriers (HBsAg positive over 6 months) 3. HBeAg positive patient, or patient who had lost HBeAg during Antiviral drug treatment 4. Antiviral drug treated patient reducing the HBV DNA level below 2000 IU/mL measured by COBAS TaqManM HBV Test (Duration of drug administration should be over 6 months and no limitation on the type of antiviral drug) 5. Patient has low ALT than 1.1 fold of upper limit of normal ALT level at screening 6. Patient is able to provide written informed consent by oneself or legal representative Exclusion Criteria: 1. Patient has liver diseases except chronic hepatitis B (i.e. hematochromatosis, alcoholic liver disease, nonalcoholic fatty liver disease, alpha-1 antitrypsin deficiency etc.) 2. Patient has one or more test results and symptoms at the screening - ALT > upper limit of normal level X 1.1 - Total bilirubin > upper limit of normal - Prothrombin time > Over 3 second than normal - Serum Albumin < 30 g/L (3 g/dL) - Patient has history of ascites, yellow jaundice, variceal hemorrhage, hepatic encephalopathy, or liver failure - Liver FibroScan > F3 (F0: no fibrosis, F1: portal fibrosis, F2: periportal fibrosis, F3: septal fibrosis, F4: cirrhosis) 3. Patient has one or more test results at the screening - Hemoglobin < 9.0 g/dL - Absolute neutrophil count (ANC) < 1.5 x 109 /L (1500 /mm3) - Platelet count < 100 x 109 /L (100 x 103 /mm3) - Serum creatinine > 1.5 mg/dL - Serum amylase > 2 x ULN and Lipase > 2 x ULN 4. Patient has history of Interferon treatment 5. Patient is pregnant or breastfeeding or intending to become pregnant during the study 6. Patient has active microbial, viral, or fungal infections in need of systemic treatment 7. Alpha-fetoprotein (AFP) > 50 ng/mL or Hepatocellular Carcinoma (HCC) patient 8. Among the patients treated with immunosuppressive drug within 6 months before screening, suspected case of the declined immunity in the opinion of the investigator 9. Patient had long term systemic treatment (more than 14 days consecutively) of high dose (over 20 mg of prednisolone or equivalent dose*) corticosteroid (Decision to participate of patient who had local treatment of corticosteroid is allowed in the opinion of the investigator) *equivalent to cortisone 125 mg, hydrocortisone 100 mg, prednisone 20 mg, methylprednisolone 16 mg, triamcinolone 16 mg, dexamethasone 3 mg, or betamethasone 2.4 mg 10. Patient diagnosed with a malignant tumor within 5 years before screening or relapsed patient (Benign tumor patient is able to participate in this study at the discretion of the investigator) 11. Patient has history of organ transplantation 12. Patient has serious disease judged by investigator such as heart failure, renal failure, and pancreatitis 13. Patient has history of serious heart disease (NYHA Functional Class III or IV heart failure, myocardial infarction within 6 months, treatment required ventricular tachyarrhythmias, or unstable angina etc.) 14. Patient has seizure disorder required anticonvulsants treatment 15. Uncontrollable diabetic patient (FBS>130mg/dl, HbA1c>7.5%) 16. Uncontrollable hypertension patient (SBP=140mmHg ?? DBP=90mmHg) 17. HCV, HDV, or HIV patient 18. Patient has a plan to participate in other clinical study, or took part in other clinical study within 1 month before enrollment 19. Patient has hypersensitivity or anaphylactic reaction for components of investigational product or HBV vaccine 20. Patient has continuous drinking (>21 units/week, 1 unit = 10g of pure alcohol) or dependence on alcohol 21. Patient concerned about the decline in daily activity or not able to understand the objectives and methods due to the psychiatric problems 22. Patient has potential to severe febrile or systemic reaction 23. Subject unacceptable in this study under the opinion of the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
CVI-HBV-002
Investigational product: CVI-HBV-002 Dose: 20ug or 40ug Frequency: 3 or 6 times Vaccination schedule: 0, 1, 2 months or 0, 1, 2, 3, 4, 5 months Administration route: Intramuscular injection

Locations

Country Name City State
Korea, Republic of Bundang CHA General Hospital Seongnam-si Gyeonggi-do

Sponsors (1)

Lead Sponsor Collaborator
CHA Vaccine Institute Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability (including incidence of adverse events or expected adverse reactions for vaccine treatment) measured for 7 days after each vaccination Occurrence of severe local and/or systemic tolerability signs and symptoms measured for 7 days after each vaccination 7 days after each vaccination
Secondary HBeAg loss HBeAg disappearance at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group) comparing with that of baseline at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group)
Secondary HBe seroconversion rate HBeAg seroconversion rate at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group) comparing with that of baseline at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group)
Secondary HBsAg loss HBsAg disappearance at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group) comparing with that of baseline at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group)
Secondary HBsAg seroconversion rate HBsAg seroconversion rate at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group) comparing with that of baseline at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group)
Secondary HBV specific T cell immunity HBV specific T cell response at the 3rd month (for 3 shot group) or 6th month (for 6 shot group) comparing with that of baseline at the 3rd month (for 3 shot group) or 6th month (for 6 shot group)
Secondary HBV DNA level HBV DNA level at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group) comparing with that of baseline at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group)
See also
  Status Clinical Trial Phase
Completed NCT03272009 - Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects Phase 1
Recruiting NCT01456312 - HBsAg Related Response Guided Therapy Phase 4
Terminated NCT01886300 - An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam N/A
Completed NCT00962975 - A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies Phase 1
Completed NCT01023230 - A Study to Assess DV-601 in Subjects With Chronic Hepatitis B Phase 1
Completed NCT00536263 - PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327) Phase 3
Terminated NCT00460850 - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B. Phase 4
Completed NCT03681132 - The Norwegian Nucleoside Analogue Stop Study Phase 4
Active, not recruiting NCT05473806 - Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes Phase 4
Withdrawn NCT01179594 - A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B. Phase 4
Recruiting NCT05057065 - A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB
Completed NCT04439539 - A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection Phase 2
Withdrawn NCT03125213 - A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects Phase 2
Active, not recruiting NCT04782375 - Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B Phase 4
Withdrawn NCT05550519 - A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment Early Phase 1
Enrolling by invitation NCT04160897 - Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis
Active, not recruiting NCT02588937 - Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Phase 4
Completed NCT02612506 - Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers Phase 1
Recruiting NCT02327416 - A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study) Phase 3
Active, not recruiting NCT02267473 - Hepatitis B Patients Under Oral Nucleos(t)Ide Treatment With Intermittent Assessment of Kidney Function